Head-to-head · Value Score
Vitara RX vs Luci
Two GLP-1 deals, scored on the same six factors. Vitara RX lands a Value Score of 91, Luci a 68. Here's who gives you the honest lower price — and where each one bites back.
Vitara RX
#4 · Grade A · Best Value
Est. first month
$99/mo
Save ~93% vs brand-nameLuci
#281 · Grade C · Watch List
Est. first month
From $99/mo (starting dose, compounded)
Save ~93% vs brand-nameThe verdict
Vitara RX takes it on Value Score, 91 to 68 — an est. $99/mo first month, with no teaser step-up baked in. Luci isn't out of it: Shoppers who want budget shoppers wanting low-cost compounded semaglutide or tirzepatide, including oral pill options.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | Vitara RX | Luci |
|---|---|---|
| Value Score | 91 (A) | 68 (C) |
| Est. first month | $99/mo | From $99/mo (starting dose, compounded) |
| Save vs brand-name | ~93% | ~93% |
| Semaglutide | $99/mo | From $99/mo (starting dose, compounded) |
| Tirzepatide | $149/mo | From $145/mo (starting dose, compounded) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | 49 states | Coverage not published |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
Vitara RX
VitaraRx is a direct-to-consumer telehealth marketplace offering compounded semaglutide and tirzepatide at flat per-drug pricing across all doses — no membership or hidden fees.
Why it's a deal
- Among the lowest flat pricing in the market — $99/mo semaglutide and $149/mo tirzepatide, all doses same price
- Names its 503A pharmacy partner (Manifest Pharmacy, Greer SC) — strong supply-chain transparency
- LegitScript Certified
- Publishes the FDA compounded-medication disclaimer
- Covers 49 states with an explicit state list, not vague "most states" language
The fine print
- No corporate legal entity disclosed — only the trade name "VitaraRx"
- No named medical director — all clinical decisions made by independent providers (marketplace model)
- All sales final — no medication returns
- Per-vial mg quantity isn't clearly disclosed, making price comparisons harder
- Doesn't ship to Alaska
Luci
Luci is a budget-focused GLP-1 telehealth platform offering compounded medications with upfront pricing: compounded semaglutide as low as $99/month and compounded tirzepatide as low as $145/month, plus oral…
Why it's a deal
- Budget-friendly compounded GLP-1 pricing (compounded semaglutide as low as $99/month, tirzepatide as low as $145/month)
- Multiple formats: compounded semaglutide and tirzepatide injections plus oral semaglutide and tirzepatide pill kits
- Upfront pricing with no insurance required and a fast 3-minute questionnaire to start
- Care delivered through DrTelx, an independent US telehealth medical group, with ongoing support and dose optimization
- HIPAA-compliant platform with a large self-reported member base (50,000+)
The fine print
- Compounded medications are not FDA-approved for weight loss (the site discloses this) — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
- Available only in select U.S. states, and the full state list is not published
- The compounding pharmacy partner is not named
- Headline prices are 'as low as' rates (asterisked) — your actual monthly cost may be higher
- No LegitScript certification displayed; marketing leans heavily on testimonials
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores Vitara RX is ranked on the Vitara RX alternatives board, and the same list for the other side is on alternatives to Luci.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.